MicroRNAs (miRNAs) play crucial roles in the pathogenesis of neuropathic pain. The present study investigated the effects of miR-448 on the progression of neuropathic pain in a rat model of chronic constriction injury (CCI) of the sciatic nerve. Reverse-transcription quantitative polymerase chain reaction was conducted to detect the gene expression. The paw withdrawal threshold (PWT) and paw withdrawal latency (PWL) were used to assess the pain threshold. The protein expression levels of interleukin (IL)-6, IL-1β and tumor necrosis factor-α (TNF-α) were detected by ELISA. The target of miR-448 was predicted by TargetScan software. The Student's t-test or one-way ANOVA were used to identify statistical differences among groups. miR-448 was persistently upregulated in CCI rats, and both mechanical allodynia and thermal hyperalgesia in CCI rats were decreased following miR-448 downregulation. The expression levels of IL-1β, IL-6 and TNF-α were significantly increased in CCI rats compared with controls, and these effects were reversed following treatment with a miR-448 inhibitor. A luciferase reporter assay revealed that sirtuin 1 (SIRT1) was a target gene of miR-448. SIRT1 was found to abrogate the effect of miR-448 on neuropathic pain development. Collectively, the results of the present study revealed that miR-448 promoted neuropathic pain in CCI rats by regulating neuroinflammation via SIRT1. Therefore, SIRT1 may be considered as a novel biomarker for neuropathic pain.
Introduction
Neuropathic pain is caused by nerve dysfunction or lesions (1) , and is caused by the response of the central and peripheral nervous systems to the nerve injury (2) . Neuropathic pain is regarded as a serious public health concern worldwide and results in poor quality of life for patients (3) . Various factors, such as surgery, trauma, toxicity and congenital disorders, can exacerbate neuropathic pain (4) . However, no effective treatments have been established for neuropathic pain. Therefore, it is of great importance to explore the molecular mechanism of this condition.
MicroRNAs (miRNAs) are a class of small and non-coding RNA molecules, which serve as post-transcriptional regulators of gene expression by binding to the 3'-untranslated region (UTR) of target mRNAs (5) . Numerous studies have suggested that miRNAs are involved in many biological processes, including cell development, proliferation, differentiation, apoptosis and the stress response (6) (7) (8) . A number of aberrantly expressed miRNAs have been identified in various types of human cancer (9, 10) . Moreover, several miRNAs have recently been reported to participate in the development of neuropathic pain. For instance, miR-98 suppresses the progression of neuropathic pain by targeting high mobility group A2 (11) . miR-206-3p acts as an inhibitor of chronic constriction injury-induced neuropathic pain by regulating the expression of histone deacetylase 4 (12) . miR-28-5p attenuates the development of neuropathic pain by binding to the 3'-UTR of zinc finger E-box-binding homeobox in vivo (13) . Notably, Lu et al (14) reported that miR-448 was differentially expressed in rat cortex following anesthesia with sevoflurane, suggesting a role for miR-448 in neurological function. On basis of these results, the present study investigated the role of miR-448 in the progression of neuropathic pain.
Materials and methods
Animal studies. A total of 62 adult female Sprague-Dawley rats with weights ranging from 180 to 210 g were purchased from the Shanghai Animal Laboratory Center. All rats were housed in individual cages with a constant temperature of 25˚C and had free access to food and water. The health and behavior of the rats were monitored every day. A rat model of neuropathic pain was established by chronic constriction injury (CCI) as previously described (15) . A total of 30 rats were randomly divided into the sham group and CCI group (n=15 rats per group). Rats were anesthetized by the intraperitoneal injection of 40 mg/kg sodium pentobarbital. The sciatic nerves on both sides were exposed and separated from the surrounding tissues. Sham-operated rats were subjected to sciatic nerve exposure and isolation without ligation. The rats were euthanized on days 0, 3, 7, 14 and 21 following surgery by the intravenous administration of 140 mg/kg pentobarbital. Total cardiac arrest, pupil dilation, muscle flaccidity and absence of reflexes were used to confirm euthanasia. As the segmental nerves L4-L6 contribute to the sciatic nerve (16) , the dorsal spinal cords of these nerves were collected immediately following euthanasia.
The experimental procedures for care and use of animals were approved by the Medical Ethics Committee of Shengli Oilfield Central Hospital (reference number, 20170016), and were performed strictly under the requirements of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Humane endpoints were followed in accordance with the OECD Guidance Document on the Recognition, Assessment and Use of Clinical Signs as Humane Endpoints for Experimental Animals Used in Safety Evaluation (2000) , and measures were taken to minimize pain and discomfort, such as a cut-off time for the pain threshold assessment.
Cell culture. Rat microglial cells (HAPI) were obtained from the American Type Culture Collection. All cells were cultured in DMEM (Lonza Group Ltd.) supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin. Cells were incubated in a 5% CO 2 incubator at 37˚C. The miR-448 mimic, miR-448 inhibitor and scrambled controls were purchased from Shanghai GenePharma Co., Ltd. The sequences were as follows: miR-448 mimic, 5'-UUG CAU AUG UAG GAU GUC CCA U-3'; miR-448 mimic NC, 5'-UUC UCC GAA CGU GUC ACG UTT-3'; miR-448 inhibitor, 5'-AUG GGA CAU CCU ACA UAU GCA A-3'; miR-448 inhibitor NC, 5'-CAG UAC UUU UGU GUA GUA CAA-3'. Lipofectamine TM 2000 (Thermo Fisher Scientific, Inc.) was used to transfect the miRNAs (100 nM) into HAPI cells according to the manufacturer's protocol. At 48 h post-transfection, the cells were harvested for the subsequent experiments.
Lentivirus (LV) production and infection. Lentiviruses delivering short hairpin (sh) RNAs against miR-448 [LV-miR-448 knockdown (KD)], sirtuin 1 [SIRT1 (LV-SIRT1 KD)] and their respective scrambled sequences (LV-miR-scrambled) were purchased from Shanghai GenePharma Co., Ltd.
A total of 32 rats were randomly assigned into four groups: Sham group, CCI + LV-miR-scrambled, CCI + LV-miR-448 KD group and CCI + LV-miR-KD + SIRT1 KD group (n=8 per group). A PE-10 polyethylene catheter was inserted into the rats to allow the delivery of the lentiviral vectors. A volume of 10 µl of 0.5% lidocaine (0.9-1.1 mg/kg) was injected into rats through an intrathecal catheter. The catheter was confirmed to be successfully inserted when paralysis of the bilateral hind limbs arose immediately after anesthesia. Then intrathecal catheter was also used for lentivirus injection (1x10 8 PFU/ml, 10 µl). All rats were euthanized 7 days postoperatively.
RNA extraction and reverse-transcription quantitative polymerase chain reaction (RT-qPCR). Total RNA was isolated from tissues or cells using a miRNeasy mini kit (Qiagen) according to the manufacturer's protocol. RT was performed using TaqMan miRNA reverse-transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. qPCR was conducted to detect the expression levels of miR-448 and SIRT1 using a SYBR Premix Ex Taq™ II commercial kit (Takara Biotechnology Co. Ltd.) and the Applied Biosystems 7900 Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The PCR conditions were as follows: 95˚C for 5 min, followed by 40 cycles of 95˚C for 30 sec, 60˚C for 30 sec, and 72˚C for 40 sec and then a final extension at 72˚C for 5 min. mRNA levels were quantified using the 2 -ΔΔCq method and normalized to the internal reference gene GAPDH or U6 (17) . Primers used in this study are as follows: miR-448, forward, 5'-GCC GAG TTG CAT ATG TAG GA-3' and reverse, 5'-ATG CAT GCC ACG GGC ATA TAC ACT-3'; SIRT1, forward, 5'-ATG AAG CAC CAA CCG TAT C-3' and reverse, 5'-CTG AAT TGA CCT TGA CTG ATG-3'; U6, forward, 5'-CGC TTC GGC AGC ACA TAT ACT AAA ATT GGA AC-3' and reverse, 5'-GCT TCA CGA ATT TGC GTG TCA TCC TTG C-3'; GAPDH: forward, 5'-AGA AGG CTG GGG CTC ATT TG-3' and reverse, 5'-AGG GGC CAT CCA CAG TCT TC-3' .
Pain threshold assessment. Behavioral testing was conducted between 9:00 a.m. and 4:00 p.m on days 0, 3, 7, 14 and 21 following surgery. The paw withdrawal threshold (PWT) was used to calculate mechanical allodynia using a calibrated electronic von Frey filament (0.5x0.5 cm 2 ; cat. no. 2393; IITC Inc. Life Science) on and the plantar surface of each hind paw. The time taken to elicit the paw withdrawal response was evaluated. Paw withdrawal latency (PWL) was used to evaluate the thermal hyperalgesia response to radiant heat using a thermal paw stimulation system (BME-410C; Institute of Biomedical Engineering, Chinese Academy of Medical Sciences). The animals were exposed to heat for 10 sec and the experiment had a cut-off time of 20 sec regardless of whether the animals reacted or not. The duration between the start of the stimulus and paw withdrawal was recorded.
ELISA. The frozen spinal cord tissues (30 mg) were dissolved in 300 µl RIPA lysis buffer (Beyotime Institute of Biotechnology) at 4˚C for 3 h and the homogenate was then centrifuged at 12,000 x g for 10 min at 4˚C to remove debris. The protein expression levels of interleukin (IL)-6 (cat. no. R6000B), IL-1β (cat. no. RLB00) and tumor necrosis factor-α (TNF-α, cat. no. RTA00) in the tissue homogenate was then dermined using ELISA kits according to the manufacturer's protocols (R&D Systems China Co., Ltd.).
Luciferase activity assay. The target gene of miR-448 was predicted using TargetScan 7.1 bioinformatics software (www.targetscan.org/vert_71). The wild-type (WT) or mutant (Mut) SIRT1 binding site in miR-448 was amplified and sub-cloned into the pGL3 basic vector (Promega Corporation). Next, 50 ng of pGL3 vectors and 200 ng of miR-448 mimics or miR-448 inhibitor were co-transfected into rat microglial cells using Lipofectamine TM 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Cells transfected with only Lipofectamine TM 2000 reagent were used as the mock transfection group. After 48 h, Luciferase activity was measured using a Dual-Luciferase Reporter Assay system (E1910; Promega Corporation) according to the manufacturer's instructions. Renilla luciferase activity was used as the internal control.
Statistical analysis. The data are presented as mean ± standard deviation. Differences between two groups were compared using Student's t-test. One-way ANOVA analysis followed by Tukey's post hoc test was used for the comparison of two or more groups. All data analyses were conducted using SPSS software (version 18.0; SPSS Inc.) and GraphPad Prism software (version 5.0; GraphPad Software, Inc.). P<0.05 was considered to indicate a statistically significant difference.
Results
Expression of miR-448 is significantly increased in a rat model of CCI. To investigate the role of miR-448 in neuropathic pain development, the expression level of miR-448 was first measured in the spinal cords of CCI and sham-operated rats. As shown in Fig. 1 , the expression level of miR-448 increased significantly in a time-dependent manner in CCI compared with sham-operated rats (P<0.05).
miR-448 downregulation inhibits the development of neuropathic pain. As miR-448 was persistently expressed in CCI rats, the downregulation of miR-448 may attenuate the development of neuropathic pain. To test this hypothesis, an miR-448 inhibitor was intrathecally administered to the rats. Compared with that in the sham-operated group, miR-448 was significantly upregulated in CCI rats, and both the PWT and PWL were decreased significantly in rats with CCI (all P<0.05; Fig. 2 ). Compared with CCI + scrambled group, miR-448 was significantly downregulated in CCI rats treated with the miR-488 inhibitor (P<0.05; Fig. 2A ). Additionally, the PWT and PWL were lower in CCI rats compared with sham-operated group, and these effects were abrogated by miR-448 downregulation (P<0.05; Fig. 2B-C) .
miR-448 downregulation depresses inflammatory cytokines levels in vivo.
To further investigate the biological effect of miR-448 on neuropathic pain, the expression levels of inflammatory cytokines were measured in CCI rats when miR-448 was downregulated. The protein levels of IL-1β, IL-6 and TNF-α were significantly increased in rats with CCI compared with those in the sham-operated group, and the levels were significantly decreased following treatment with the miR-448 inhibitor (all P<0.05; Fig. 3 ).
miR-448 directly targets the 3'UTR of SIRT1. The potential mechanism of miR-448 in regulating neuropathic pain was further explored, and the potential target gene of miR-448 was investigated. The TargetScan analysis suggested that the 3'-UTR of SIRT1 contained a binding region for miR-448 ( Fig. 4A) . To confirm the transfection efficiency of miR-448 mimic or inhibitor, the relative expression of miR-448 was quantified using RT-qPCR. It was noted that miR-448 mimic transfection significantly increased miR-448 level in HAPI cells compared with the miR scrambled control, whereas miR-448 inhibitor transfection significantly decreased the miR-448 expression level (P<0.05; Fig. 4B ). The luciferase reporter assay suggested that treatment with the miR-448 mimic significantly attenuated the luciferase activity in WT SIRT1 3'UTR transfected cells, compared with treatment with miR-scrambled control, while the inhibition of miR-448 promoted luciferase activity (Fig. 4C) . However, the miR-448 mimic did not affect the luciferase activity in Mut SIRT1 3'UTR transfected cells. Additionally, the RT-qPCR analysis results showed that the reduced SIRT1 mRNA expression in rats with CCI was significantly upregulated following miR-448 inhibitor treatment (P<0.05; Fig. 4D ).
Effect of miR-448 on neuropathic pain is reversed by SIRT1.
To detect whether miR-448 affects the development of neuropathic pain by regulating SIRT1 expression, rescue experiments were performed. SIRT1 mRNA expression levels were detected in rats subjected to CCI co-infected with miR-448 inhibitor and shSIRT1 lentiviruses. The increased SIRT1 mRNA expression level induced by miR-448 inhibitor treatment was significantly decreased following shSIRT1 infection (P<0.05; Fig. 5A ). Furthermore, the suppressive effects of the miR-448 inhibitor on mechanical allodynia and thermal hyperalgesia were substantially reversed by shSIRT1 infection (Fig. 5B-C ; all P<0.05). Additionally, the decreased expression of inflammatory cytokines, including IL-1β, IL-6 and TNF-α, caused by the miR-448 inhibitor, was also reversed by shSIRT1 (all P<0.05; Fig. 5D-F) . The data indicated that miR-448 enhanced neuropathic pain by targeting SIRT1.
Discussion
Neuropathic pain can be caused by different neurological diseases resulting from injury of the peripheral nerves. Patients with cancer, diabetes and acquired immunodeficiency syndrome are likely to suffer from neuropathic pain (18) (19) (20) . It has been noted that the expression of IL-1β, IL-6 and TNF-α can be induced by nerve surgery (21) , indicating that inflammation could play a crucial role in the progression of neuropathic pain (22) . miRNAs are a class of non-coding RNAs 18-24 nucleotides in length. A number of miRNAs have been shown to be aberrantly expressed in various types of diseases, including inflammatory diseases, heart diseases and several types of human cancer (23, 24) . Increasing evidence has reported that miRNAs may be involved in the development of neuropathic pain development (11, 12) . Altered expression of miR-448 has been detected in various human diseases. For instance, miR-448 was expressed at low levels in glioma cells, and suppressed cell proliferation and promoted apoptosis (25) . Zhang et al (26) suggested that miR-448 was highly expressed in vascular smooth muscle cells (VSMCs) from coronary atherosclerotic plaques, and overexpression of miR-448 promoted VSMC migration. Hong et al (27) indicated that miR-448 is upregulated in gastric cancer tissues compared with adjacent non-tumor samples, and can enhance the glycolytic metabolism of gastric cancer cells by downregulating lysine demethylase 2B (KDM2B). All evidence suggests the various roles of miR-448 in different diseases. In the present study, miR-448 was significantly increased in CCI rat compared with the sham-operated group, and downregulation of miR-448 markedly attenuated the progression of neuropathic pain. A previous study suggested that miR-448 was upregulated in the spinal cord tissues of spinal cord ischemia/reperfusion injury model rats, as well as in cells treated with hypoxia and that downregulation of miR-448 inhibited apoptosis in nerve cells and improved neurological function (28) . Additionally, Lu et al (14) reported that the expression level of miR-448 was significantly upregulated in rats treated with sevoflurane compared with controls (14) . An et al indicated that lead exposure resulted in the upregulation of miR-448 in rat models (29) . The aforementioned studies support the results obtained in the present study.
Previous evidence has suggested that neuroinflammation plays a crucial role in the development of neuropathic pain (30) . IL-1β, IL-6 and TNF-α are commonly implicated as inflammation-associated cytokines (31, 32) . In the present study, the ELISA results suggested that the expression levels of IL-1β, IL-6, and TNF-α were decreased in the spinal cords of rats following treatment with the miR-448 inhibitor. This suggested that the downregulation of miR-448 markedly decreased the progression of neuropathic pain through by attenuating neuroinflammation. miRNAs exert their functions by binding to the target genes at a post-transcriptional level (33, 34) . Previous evidence has suggested that miR-448 exhibits differing functions in human diseases. For example, Su et al (25) revealed that miR-448 suppresses cell proliferation and promotes apoptosis in glioma by downregulating cortactin. Yang et al (35) reported that miR-448 contributes to the development of osteoarthritis by downregulating matrilin-3 expression. Zhang et al (26) suggested that overexpression of miR-448 enhanced cell proliferation and migration in vascular smooth muscle cells (VSMCs) by targeting MEF2C. Previous studies reported that several genes are target genes of miR-448 (29, 36) ; however, only one of those target genes, SIRT1, was investigated in the present study. For example, Hong et al (27) reported that miR-448 can promote glycolytic metabolism in gastric cancer, and KDM2B was revealed to be the target gene that can repress glycolysis. Insulin like growth factor 1 receptor (IGF1R) was reported to be the target gene of miR-448 in colorectal cancer cells and IGF1R gene overexpression reversed the suppressive effect of miR-448 on tumor progression in vitro (36) . Additionally, Wang et al (28) suggested that downregulation of miR-448 can relieve SCII by upregulating SIRT1. In the present study, luciferase reporter assay results confirmed that SIRT1 was the target of miR-448. Additionally, rescue experiments were performed to detect whether miR-448 affects the development of neuropathic pain by regulating SIRT1 expression. Overexpression of SIRT1 reversed the effect of miR-448 on neuropathic pain development. Therefore, miR-448 may enhance neuropathic pain by targeting SIRT1. A major study reported that downregulation of miR-448 relieved SCII, inhibited apoptosis of nerve cells and improved neurological function by upregulating SIRT1 (28) , which was in accordance with the results obtained in the present study.
The neuroprotective effect of SIRT1 has been widely investigated in previous studies. Fujita and Yamashita (37) suggested that SIRT1 is involved in the protection of neurons from degeneration in models of neurological diseases, including traumatic brain injury and Alzheimer's disease (37) . Zhao et al (38) suggested that the expression level of SIRT1 was increased in resveratrol-treated animals, and exerted neuroprotective effects on spinal cord injury. Additionally, Zhang et al (39) reported that SIRT1 alleviates neuropathic pain in rats with type 2 diabetes mellitus. Furthermore, a recent study reported that downregulation of miR-377 could decrease proinflammatory cytokine release through upregulation of SIRT1 (40) . SIRT1 has also been reported to regulate the secretion of inflammatory factors induced by high glucose or hypoxia (41), suggesting the crucial role of SIRT1 in host inflammatory responses. The aforementioned studies indicate that SIRT1 exhibits a neuroprotective role by suppressing neuroinflammation, which was consistent to the results obtained in the present study. In conclusion, the present study demonstrated that miR-448 promoted the development of neuropathic pain in a rat model of CCI by regulating neuroinflammation via SIRT1. Therefore, miR-448 may serve a novel target for neuropathic pain treatment. 
